

Male infertility

Dimitrios G. Goulis

Professor of Reproductive Endocrinology

Aristotle University of Thessaloniki



Unit of Reproductive Endocrinology
First Department of Obstetrics and Gynecology
Aristotle University of Thessaloniki


Conflict of interests

- During the last three years, I have received research, educational and travel grants from scientific societies and pharmaceutical companies.
- I am currently or have been:
 - President, Hellenic Society of Andrology (2013 - 2017)
 - President-Elect, European Menopause and Andropause Society (2019 - 2021)
 - Secretary General, European Academy of Andrology (2014 - 2018)
 - Director, Training Centre European Academy of Andrology (2013 - 2019)
 - Member of the Executive Board, Hellenic Society of Endocrinology (2011 - 2013)
 - Member of the Executive Board, Hellenic Society of Climacteric and Menopause (2013 - 2019)
 - Associate Editor, Human Reproduction (2009 - 2013)
 - Associate Editor, Hormones (2012 - 2019)
 - Member of the Editorial Board, Andrology (2012 - 2019)
 - Member of the Editorial Board, Maturitas (2015 - 2019)
 - Member of the Editorial Board, Metabolism (2015 - 2019)
 - Member of the Editorial Board, Journal of Endocrinological Investigation (2014 - 2019)
 - Associate Editor, Human Reproduction Open (2017 - 2019)
 - Associate Editor, Human Andrology (2017 - 2019)
- None of the above can be considered as a conflict of interest for today's lecture.


Aims

- Evaluation and etiologic approach of male infertility
- Selection of the optimal management method

Diagnostic approach



Diagnostic approach



Causes of male infertility

• Cause	Prevalence (%)
• Idiopathic infertility	32
• Varicocele	17
• Endocrine causes	9
• Infections	9
• Cryptorchidism	8
• Sexual dysfunction	6
• Systematic diseases	5
• Anti-sperm antibodies	4
• Testicular tumors	2
• Obstruction	1
• Other causes	7

Diagnostic evaluation

- Clinical
- Hormonal
- Seminal
- Imaging
- Histologic
- Genetic

Diagnostic evaluation

- Clinical
- Hormonal
- Seminal
- Imaging
- Histologic
- Genetic

Clinical evaluation

- History

- Primary or secondary infertility, duration of infertility, mumps, cryptorchidism, trauma, surgical procedures, infections, recent febrile episodes, chemotherapy or radiotherapy, medications, family history of infertility, cystic fibrosis, mental retardation, female factor

- Clinical evaluation

- Testicular size, secondary sexual characteristics, presence and consistence of epididymides and vas deferens, varicocele, digital examination

Clinical evaluation


- History

- Primary or secondary infertility, duration of infertility, mumps, cryptorchidism, trauma, surgical procedures, infections, recent febrile episodes, chemotherapy or radiotherapy, medications, family history of infertility, cystic fibrosis, mental retardation, female factor



- Clinical evaluation

- Testicular size, secondary sexual characteristics, presence and consistence of epididymides and vas deferens, varicocele, digital examination

Clinical evaluation



Clinical evaluation



Diagnostic evaluation

- Clinical
- **Hormonal**
- Seminal
- Imaging
- Histologic
- Genetic

Hormonal evaluation

- FSH
- LH
- Testosterone, total
- Prolactin
- Thyroid evaluation
- Inhibin B (Inh B)
- Anti-Müllerian hormone (AMH)

FSH

- Differential diagnosis between central (hypothalamus, pituitary) and peripheral (testicular) failure
- Variation <10%
- Strong correlation with:
 - Testicular histology
 - Sperm count
 - GnRH stimulation


Inh B

- TGF- β family glycoprotein
- Exclusive Sertoli cell product
- Endocrine action:
 - FSH inhibition
- Paracrine effects
- Positive correlation with sperm count and testicular size
- Prognostic factor for TESE

AMH

- TGF- β family glycoprotein
- Sertoli cell product
- Endocrine action:
 - Müllerian duct reversal
- Paracrine and autocrine actions
- Prognostic factor for TESE

Testicular histology



Diagnostic evaluation

- Clinical
- Hormonal
- **Seminal**
- Imaging
- Histologic
- Genetic

Semen reference ranges

- Liquefaction
 - < 60 min
- Appearance
 - Non-translucent
- Viscosity
 - Filaments < 2 cm
- pH
 - > 7.2
- Volume
 - > 1.5 ml
- Concentration
 - > 15 millions/ ml
- Motility
 - > 40 (a + b + c)
 - > 32 (a + b)
- Normal morphology
 - > 4%

Semen reference ranges

Table II Distribution of values, lower reference limits and their 95% CI for semen parameters from fertile men whose partners had a time-to-pregnancy of 12 months or less

	N	Centiles		5	(95% CI)	10	25	50	75	90	95	97.5
		2.5	(95% CI)									
Semen volume (ml)	1941	1.2	(1.0–1.3)	1.5	(1.4–1.7)	2	2.7	3.7	4.8	6	6.8	7.6
Sperm concentration (10^6 /ml)	1859	9	(8–11)	15	(12–16)	22	41	73	116	169	213	259
Total number (10^6 /Ejaculate)	1859	23	(18–29)	39	(33–46)	69	142	255	422	647	802	928
Total motility (PR + NP, %)*	1781	34	(33–37)	40	(38–42)	45	53	61	69	75	78	81
Progressive motility (PR, %)*	1780	28	(25–29)	32	(31–34)	39	47	55	62	69	72	75
Normal forms (%)	1851	3	(2.0–3.0)	4	(3.0–4.0)	5.5	9	15	24.5	36	44	48
Vitality (%)	428	53	(48–56)	58	(55–63)	64	72	79	84	88	91	92


*PR, progressive motility (WHO, 1999 grades a + b); NP, non-progressive motility (WHO, 1999 grade c).

The values are from unweighted raw data. For a two-sided distribution the 2.5th and 97.5th centiles provide the reference limits; for a one-sided distribution the fifth centile provides the lower reference limit.


Definitions

- **Oligo-astheno-teratozoospermia**
 - Low sperm number – motility – morphology
- **Azoospermia**
 - No presence of sperm, even after centrifugation of semen
 - Transient – permanent
- **Cryptozoospermia**
 - No presence of sperm, after the initial inspection
 - Presence of sperm, after centrifugation of semen
- **Aspermia**
 - No presence of semen


Sperm concentrations



Concentration




Concentration



Concentration




Motility




Specimen 524

Motility






Specimen 623

Aggregations




Agglutinations



Normal sperm




Head defect




Neck defect




Tail defect



Tail defect



Cytoplasmic residual




Semen reference ranges

- Liquefaction
 - < 60 min
- Appearance
 - Non-translucent
- Viscosity
 - Filaments < 2 cm


- pH
 - > 7.2

- Volume
 - > 1.5 ml
- Concentration
 - > 15 millions/ ml
- Motility
 - > 40 (a + b + c)
 - > 32 (a + b)
- Normal morphology
 - > 4%


Anatomy of male reproductive system




Diagnostic algorithm




Anatomy of male reproductive system




Diagnostic algorithm




Anatomy of male reproductive system




Diagnostic algorithm




Anatomy of male reproductive system



Diagnostic algorithm



Anatomy of male reproductive system




Semen evaluation

- Spermogram
- Biochemical evaluation of seminal plasma
- Semen culture
- Immunological evaluation
- Acrosome reaction
- Sperm DNA fragmentation
- Functional tests

Semen evaluation

- Spermiogram
- **Biochemical evaluation of seminal plasma**
- Semen culture
- Immunological evaluation
- Acrosome reaction
- Sperm DNA fragmentation
- Functional tests

Anatomy of male reproductive system



Semen evaluation

- Spermogram
- Biochemical evaluation of seminal plasma
- Semen culture
- Immunological evaluation
- Acrosome reaction
- **Sperm DNA fragmentation**
- Functional tests


Pathophysiology

- Mechanisms
 - Oxidative: Reactive Oxygen Species (ROS)
 - Anti-oxidative: Antioxidant Scavenging Systems (ASS)
- Oxidative stress in male reproductive system results in sperm membrane damage and sperm DNA fragmentation

Oxidative stress


FIGURE 1

Major mechanisms of inducing DNA damage in spermatozoa during either the production or the transport of sperm cells: (i) apoptosis during the process of spermatogenesis; (ii) DNA strand breaks produced during the remodelling of sperm chromatin during the process of spermiogenesis; (iii) post-testicular DNA fragmentation induced, mainly by oxygen radicals, during sperm transport through the seminiferous tubules and the epididymis (increasing DNA damage is indicated by size of red flashes and gradient darkening in tract); (iv) DNA fragmentation induced by endogenous caspases and endonucleases; (v) DNA damage induced by radiotherapy and chemotherapy; and (vi) DNA damage induced by environmental toxicants.



Sakkas. Sperm DNA fragmentation. Fertil Steril 2010.

Sperm DNA fragmentation



Evaluation methods



- Direct

- COMET
- TUNEL
- NT
- DBD-FISH

- Indirect

- SCSA
- AOT
- Halosperm

Flow cytometry



Anti-oxidative substances

- Glutathione and vitamin E
- Free or total carnitine, α -glycosidase
- Carnitine and acetyl-carnitine
- Selenium and vitamin E
- Zinc and folid acid

Bhardwaj A, et al. Asian J Androl 2000, 2:225

Zopfgen A, et al. Hum Reprod 2000, 15:840

Vicari E, et al. Hum Reprod 2001, 16:2338


Keskes-Ammar L, et al. Arch Androl 2003, 49:83

Wong WY, et al. Fertil Steril 2002, 77:491


Diagnostic evaluation

- Clinical
- Hormonal
- Seminal
- **Imaging**
- Histologic
- Genetic


Testicular ultrasound



Testicular Triplex



Transrectal ultrasound




Diagnostic evaluation

- Clinical
- Hormonal
- Seminal
- Imaging
- **Histologic**
- Genetic


Testicular FNA and TESE



Normal spermatogenesis




TESE




FNA

Hypospermatogenesis




TESE




FNA

Spermatogenesis arrest




TESE




FNA

Sertoli cell-only syndrome



TESE




FNA

Prognosis of testicular extraction

A

		FSH (U/L)						
		≤ 2.5	2.6–5.0	5.1–10.0	10.1–15.0	15.1–20.0	20.1–30.0	> 30
Bi-testicular volume (mL)	< 10						25	33
	10–19			25	40	40	36	33
	20–29			60	57	30	27	46
	30–39		60	62	36	21	22	29
	40–59		90	79	33			
	≥ 60							

microTESE



Sperm cryopreservation




Diagnostic evaluation

- Clinical
- Hormonal
- Seminal
- Imaging
- Histologic
- Genetic

Karyotype



Yq microdeletions



- Three main areas Yq

Vogt PH, et al. Hum Mol Genet 1996, 7:933

- Azoospermia / severe OAT: 3%

Osterlund C, et al. Int J Andr 2000, 23:225

Cystic fibrosis

- Congenital bilateral agenesis of vas deferens (CBAVD)

[Claustres M, et al. Hum Mutat 2000, 16:143](#)

- Obstructive azoospermia

[Jarvi K, et al. Lancet 1995, 345:1578](#)

- Congenital bronchiectasis

[Girodon E, et al. Eur J Hum Genet 1997, 5:149](#)

- Chronic pancreatitis

[Sharer N, et al. N Eng J Med 1998, 339:645](#)

Genetics of male infertility

Human Reproduction, Vol.25, No.6 pp. 1383–1397, 2010

Advanced Access publication on April 8, 2010 doi:10.1093/humrep/deq081

human
reproduction

ORIGINAL ARTICLE *Andrology*

Evaluation of 172 candidate polymorphisms for association with oligozoospermia or azoospermia in a large cohort of men of European descent


Kenneth I. Aston¹, Csilla Krausz^{2,3}, Ilaria Laface², E. Ruiz-Castané³, and Douglas T. Carrell^{1,4,5,*}

¹Andrology and IVF Laboratories, University of Utah School of Medicine, Salt Lake City, UT, USA ²Andrology Unit, Department of Clinical Physiopathology, University of Florence, Florence, Italy ³Andrology Service, Fundació Puigvert, Barcelona, Spain ⁴Department of Surgery, Department of Obstetrics and Gynecology, University of Utah School of Medicine, Salt Lake City, UT, USA ⁵Department of Physiology, University of Utah School of Medicine, Salt Lake City, UT, USA

*Correspondence address. E-mail: douglas.carrell@hsc.utah.edu

Submitted on January 26, 2010; resubmitted on March 2, 2010; accepted on March 9, 2010

Sperm FISH



Sperm disomy: 24,XY

Aims

- Evaluation and etiologic approach of male infertility
- Selection of the optimal management method

Male infertility - 1

Etiology

- Kallmann syndrome
- Prolactinoma
- Hyperthyroidism
- Hypothyroidism

Etiologic approach

- Gonadotropins
- Dopamine agonists
- Anti-thyroid drugs
- L-thyroxine

Male infertility - 2

Etiology

- Infections
- Varicocele
- Obstruction

Oriented approach

- Antibiotics
- Surgery
- Microsurgical approach

Male infertility - 3


Etiology

- Idiopathic infertility

Empirical approach

- Citric clomiphene / tamoxifen
- Gonadotropins
- Testosterone
- Anti-oxidants / Vitamins
- Insemination (IUI)
- ICSI

Citric clomiphene



Testicular dysgenesis

Human Reproduction Vol.16, No.5 pp. 972–978, 2001


OPINION

Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects


N.E.Skakkebæk¹, E.Rajpert-De Meyts and K.M.Main

Department of Growth and Reproduction, Copenhagen University Hospital, Copenhagen, Denmark

Testicular dysgenesis



Testicular dysgenesis



Male infertility

- Application of modern diagnostic methods for the **etiologic diagnosis** of the cases
- **Appropriate evaluation** of the patients and their **classification into subgroups** to select the cases for the application of the optimal therapeutical approaches

Unit of Reproductive Endocrinology

Professor D.G. Goulis

Professor emeritus J. Papadimas

PhD candidates and Post-doc researchers

C. Tsametis (endocrinologist)

P. Poulakos (endocrinologist)

P. Iliadou (endocrinologist)

C. Dimopoulou (endocrinologist)

E. Kintiraki (endocrinologist)

S. Paschou (endocrinologist)

P. Anagnostis (endocrinologist)

I. Litsas (endocrinologist)

G. Kanakis (endocrinologist)

G. Mintziori (endocrinologist)

A. Mousiolis (endocrinologist)

E. Billa (endocrinologist)

K. Papadimitriou (endocrinologist)

V. Harizopoulou (midwife)

E. Tsirou (dietician)

E. Taousani (midwife)

D. Savvaki (physical education)

N. Athanasiadi (dietician)

I. Koptsi (psychologist)

Departments of Physical Education

Professor emeritus S. Tokmakidis

Associate professor K. Dipla

Professor A. Zafiridis



First Department of Obstetrics and Gynecology

Aristotle University of Thessaloniki

Professor G.F. Grimbizis

